Are These Biotech Companies Buyout Candidates? Deal Or No Deal?

(RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year.

In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry.

In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies.

Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time.

1. Amarin Corporation plc (AMRN)
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »